How Does Gemtesa Work? Mechanism of Action Explained in Plain English

Understanding how your medication works can help you use it more effectively and feel confident about your treatment. Here's a plain-English breakdown of exactly how Gemtesa (vibegron) works in your body to calm overactive bladder symptoms.

The Problem: Why Does Overactive Bladder Happen?

Your bladder is a muscular organ that stores urine until you're ready to void. The main muscle in your bladder wall is called the detrusor muscle. In a healthy bladder, this muscle stays relaxed as the bladder fills, and contracts only when you intentionally choose to urinate.

In overactive bladder (OAB), the detrusor muscle fires involuntarily — contracting unexpectedly while the bladder is filling. This creates that sudden, intense urge to urinate that patients with OAB experience. If the contraction is strong enough, it causes leakage before you can reach a bathroom.

What Are Beta-3 Adrenergic Receptors?

Your body has adrenergic receptors throughout many tissues — these are proteins on cell surfaces that respond to adrenaline (epinephrine) and similar signaling molecules. Beta-3 adrenergic receptors (β3-ARs) are found in bladder tissue, particularly in the detrusor muscle. When activated, they trigger a relaxation response in the bladder muscle.

Think of β3 receptors as a "calm down" switch for the bladder. When these receptors are turned on, the bladder relaxes and its capacity increases — meaning it can hold more urine before sending urgent signals to your brain.

How Gemtesa Activates the Beta-3 Pathway

Gemtesa (vibegron) is a selective agonist of the beta-3 adrenergic receptor. An "agonist" is a molecule that binds to a receptor and activates it. Here's the step-by-step process after you take a Gemtesa tablet:

Vibegron binds to β3 receptors on the detrusor smooth muscle cells in the bladder wall.

Receptor activation triggers a G-protein cascade — a chain of molecular signals inside the cell.

The enzyme adenylate cyclase is activated, which produces more cyclic adenosine monophosphate (cAMP) inside the cell.

Elevated cAMP activates protein kinase A (PKA), which reduces intracellular calcium levels.

Lower calcium inhibits myosin (the protein responsible for muscle contraction), preventing the detrusor from contracting.

The net result: the bladder muscle relaxes, bladder capacity increases, and the urgency signals decrease.

Why Gemtesa Is Different From Anticholinergic OAB Drugs

Older OAB medications like oxybutynin, solifenacin, and tolterodine work by blocking muscarinic (acetylcholine) receptors — essentially blocking the "contract" signal to the bladder. While effective, these receptors are found throughout the body, including the brain, salivary glands, gut, and eyes. Blocking them systemically causes dry mouth, constipation, blurred vision, and cognitive effects.

Gemtesa works differently — it doesn't block any receptor. Instead, it activates the β3 receptor specifically in bladder tissue to trigger relaxation. Beta-3 receptors are highly concentrated in bladder smooth muscle. And critically: Gemtesa does not cross the blood-brain barrier, so it has no effect on the brain's receptors — which is why it causes no cognitive side effects.

Why Gemtesa Is More Selective Than Mirabegron

Mirabegron (Myrbetriq) is the other beta-3 agonist for OAB. Both work by the same mechanism, but vibegron is more selective for the β3 receptor and has a different metabolic profile. Mirabegron inhibits the CYP2D6 enzyme, which metabolizes about 25% of all medications — leading to potential drug-drug interactions. Vibegron does not inhibit or induce CYP2D6 or other cytochrome P450 enzymes, making it safer for patients on multiple medications.

For more on dosing, uses, and what to expect when starting Gemtesa, see What Is Gemtesa? Uses, Dosage, and What You Need to Know.